Baseline patient demographics
| Selected patient demographics | Stable (n=26) | Strain displacement (n=13) |
| Age at enrolment years | 66.7 (47.9, 72.7) | 61.46 (41, 71) |
| Duration of follow-up years | 2.8 (1, 7) | 4.8 (1, 10.4) |
| FEV1 % predicted | 51 (39, 65) | 58 (40.5, 78.5) |
| Respiratory comorbidities | ||
| Sinusitis | 11 (42) | 6 (46) |
| Reactive airway disease | 7 (27) | 3 (23) |
| COPD | 8 (31) | 1 (8) |
| Aetiology | ||
| Idiopathic | 13 (50) | 4 (31) |
| Post-infective | 13 (50) | 7 (54) |
| Immunodeficiency | 1 (8) | |
| Other | 1 (8) | |
| Recorded antibiotics used | ||
| Inhaled tobramycin | 6 (23) | 3 (23) |
| Azithromycin | 6 (23) | 1 (8) |
| Ciprofloxacin | 3 (12) | 3 (23) |
| Additional therapies | ||
| Inhaled β2-agonist | 23 (88) | 10 (77) |
| Inhaled CS | 16 (62) | 5 (38) |
| Ipratropium bromide | 2 (8) | 6 (46) |
| Systemic CS | 5 (19) | 2 (15) |
| Spiriva | 6 (23) | 2 (15) |
| Long-term oxygen therapy | 12 (46) | 5 (38) |
Data are presented as n (%) or median (interquartile range). FEV1: forced expiratory volume in 1 s; COPD: chronic obstructive pulmonary disease; CS: corticosteroid.